Pliant Therapeutics Stock Price, News & Analysis

Pliant Therapeutics, Inc. (Nasdaq: PLRX) is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. According to the company’s public disclosures, Pliant concentrates on novel therapies for fibrotic diseases, solid tumors and muscular dystrophies, using integrin receptor biology as the foundation of its research and development efforts.

The company describes itself as a late-stage or clinical-stage biopharmaceutical organization in its press releases, emphasizing programs that target fibrosis and related conditions. Its work centers on small molecules and monoclonal antibodies designed to modulate specific integrins, which are cell-surface receptors involved in processes such as tissue remodeling, fibrosis and immune regulation.

Core programs and pipeline focus

Pliant’s disclosures highlight several key product candidates and research programs:

• Bexotegrast (PLN-74809) – An oral, small molecule, dual selective inhibitor of the αvβ6 and αvβ1 integrins. The company has described bexotegrast as its lead product candidate for the treatment of idiopathic pulmonary fibrosis (IPF), a fibrotic lung disease. In various press releases, Pliant notes that bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA), and Orphan Drug Designation from the European Medicines Agency in IPF. Pliant has also reported that development of bexotegrast in IPF within the BEACON-IPF trial was discontinued following safety and efficacy review, and that close-out activities for this Phase 2b/3 trial have been underway.
• PLN-101095 – An oral, small molecule, dual-selective inhibitor of the αvβ8 and αvβ1 integrins. Pliant reports that PLN-101095 is being evaluated in a first-in-human Phase 1, open-label, dose-escalation trial in patients with advanced or metastatic solid tumors that are resistant or refractory to immune checkpoint inhibitors. The program is designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity, both as monotherapy and in combination with the immunotherapy pembrolizumab.
• PLN-101325 – A monoclonal antibody agonist of integrin α7β1. The company states that PLN-101325 has received regulatory clearance for a Phase 1 study targeting muscular dystrophies, reflecting Pliant’s application of integrin biology to neuromuscular disease.

In addition to these clinical and near-clinical programs, Pliant describes an early-stage platform that includes preclinical research focused on tissue-specific delivery and internalization of drug payloads using integrin receptor-binding molecules. Public statements reference a proprietary library of integrin-binding molecules and assay systems designed to explore tissue-specific targeting and drug delivery across multiple disease areas.

Scientific and therapeutic focus

Pliant’s work, as described in its news releases, is centered on diseases where fibrosis, immune evasion or tissue degeneration play a central role. In fibrotic lung disease, the company has reported data on bexotegrast’s effects on markers of TGF-β signaling and fibrogenesis in human precision-cut lung slices and on biomarker analyses across interstitial lung disease (ILD) subtypes. These disclosures emphasize the company’s interest in understanding cell-specific pharmacodynamic effects and biomarker signatures in fibrotic conditions.

In oncology, Pliant’s communications describe PLN-101095 as an integrin αvβ8 and αvβ1 inhibitor intended to block activation of transforming growth factor-β (TGF-β) in the tumor microenvironment. The company states that activated TGF-β can foster an immunosuppressive tumor microenvironment that contributes to resistance to immune checkpoint inhibitors. By targeting integrins involved in TGF-β activation, Pliant aims to modulate the tumor microenvironment in patients with solid tumors that have become resistant to existing immunotherapies.

For muscular dystrophies, Pliant’s description of PLN-101325 as a monoclonal antibody agonist of integrin α7β1 indicates a focus on integrin-mediated mechanisms in skeletal muscle. The company’s public materials position this program within its broader integrin-based platform, but detailed clinical data have not been included in the provided disclosures.

Regulatory designations and development stage

The company has reported that bexotegrast has received multiple regulatory designations in IPF, including Fast Track Designation and Orphan Drug Designation from the FDA, and Orphan Drug Designation from the European Medicines Agency. These designations, as described by Pliant, relate specifically to the IPF indication. Pliant’s press releases also describe it as a late-stage or clinical-stage biopharmaceutical company, reflecting the presence of advanced clinical trials such as the BEACON-IPF Phase 2b/3 study and Phase 1 oncology trials.

Pliant has also publicly discussed strategic realignment of its workforce and operations, including reductions in workforce and cost-saving actions. According to the company, these steps were intended to extend its cash runway and support execution of clinical trials, including potential late-stage studies, while winding down the BEACON-IPF program in IPF.

Platform and research capabilities

In its corporate updates, Pliant describes a discovery platform built around integrin receptor biology. Elements mentioned in public disclosures include:

• A proprietary library of integrin-binding molecules.
• Screening assay systems that assess binding, integrin conformation and ligand-induced internalization.
• Preclinical research programs focused on tissue-specific delivery and internalization of drug payloads via integrin receptors, including work on delivering small interfering RNAs (siRNAs) to skeletal muscle cells, adipocytes and renal cells.

These platform capabilities are presented by the company as a basis for discovering and developing integrin-targeted therapies and for exploring tissue-specific drug delivery approaches across multiple disease areas.

Stock listing and sector classification

Pliant Therapeutics, Inc. is listed on The Nasdaq Stock Market LLC under the ticker symbol PLRX, as indicated in its SEC filings. Based on the provided classification, the company is associated with the Medicinal and Botanical Manufacturing industry within the broader Manufacturing sector. Pliant’s own descriptions refer to it as a biopharmaceutical or biotechnology company focused on integrin-based therapeutics.

Risk and regulatory disclosures

Pliant’s press releases include forward-looking statements and refer readers to risk factor discussions in its periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These disclosures highlight uncertainties related to drug development, clinical trial timing and outcomes, regulatory processes, financing needs and other factors that can affect a clinical-stage biopharmaceutical company.

FAQs about Pliant Therapeutics, Inc. (PLRX)

• What does Pliant Therapeutics, Inc. do?
  Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. The company’s public materials emphasize programs in fibrotic diseases, solid tumors and muscular dystrophies, built on integrin receptor biology.
• What are Pliant’s main product candidates?
  According to the company’s disclosures, key product candidates include bexotegrast (PLN-74809), an oral dual selective inhibitor of αvβ6 and αvβ1 integrins for idiopathic pulmonary fibrosis; PLN-101095, an oral dual-selective inhibitor of αvβ8 and αvβ1 integrins for solid tumors; and PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies.
• What is bexotegrast and what indications has Pliant discussed?
  Bexotegrast (PLN-74809) is described by Pliant as an oral, small molecule, dual selective inhibitor of αvβ6 and αvβ1 integrins. The company has highlighted its development in idiopathic pulmonary fibrosis and has noted regulatory designations in IPF. Pliant has also reported that development of bexotegrast in IPF within the BEACON-IPF trial was discontinued after safety and efficacy review.
• What is PLN-101095 and how is it being studied?
  PLN-101095 is an oral small molecule inhibitor of integrins αvβ8 and αvβ1. Pliant reports that it is being evaluated in a Phase 1, open-label, dose-escalation trial in patients with advanced or metastatic solid tumors that are resistant or refractory to immune checkpoint inhibitors, both as monotherapy and in combination with pembrolizumab.
• What is PLN-101325?
  PLN-101325 is described as a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies. Pliant states that it has received regulatory clearance to conduct a Phase 1 study of this candidate.
• How does Pliant describe its drug discovery platform?
  The company describes a platform that includes a proprietary library of integrin-binding molecules, screening assays that evaluate integrin binding and conformation, and preclinical research on tissue-specific delivery and internalization of drug payloads using integrin receptor-binding molecules.
• Which regulatory designations has bexotegrast received according to Pliant?
  Pliant’s press releases state that bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration in idiopathic pulmonary fibrosis, and Orphan Drug Designation from the European Medicines Agency in IPF.
• On which exchange does Pliant Therapeutics trade and what is its ticker?
  SEC filings indicate that Pliant Therapeutics, Inc. trades on The Nasdaq Stock Market LLC under the ticker symbol PLRX.
• How does Pliant describe its therapeutic focus areas?
  In its public statements, Pliant describes a focus on fibrotic diseases, solid tumors that are resistant to immune checkpoint inhibitors, and muscular dystrophies, all approached through integrin-based therapeutics.
• Where can investors find more detailed risk information?
  Pliant’s press releases refer investors to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of its periodic reports filed with the SEC, which are available through the SEC’s public website.